Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafamidis - Pfizer

Drug Profile

Tafamidis - Pfizer

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Tafamidis free acid; Tafamidis meglumine; VYNDAMAX; Vyndaqel

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Cardiovascular therapies; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy; Cardiomyopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy; Cardiomyopathies

Most Recent Events

  • 28 Aug 2019 No recent reports of development identified for phase-I development in Amyloid polyneuropathy(In volunteers) in Belgium (PO, Tablet)
  • 28 Aug 2019 No recent reports of development identified for phase-I development in Cardiomyopathies(In volunteers) in Singapore (PO, Capsule)
  • 06 May 2019 FDA assigns PDUFA action date of July 2019 for tafamidis meglumine (20mg, capsule) for transthyretin amyloid cardiomyopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top